Adult: 5 mg once daily. Patients with intermittent allergic rhinitis must be managed according to the evaluation of disease history, treatment may be discontinued after the symptoms are resolved and reinitiated upon reappearance; in case of persistent allergic rhinitis, continuous treatment may be considered during the periods of allergen exposure. Treatment recommendations may vary among countries and individual products (refer to specific product guidelines). Child: 1-5 years As oral solution or syrup: 1.25 mg once daily; 6-11 years As orodispersible tab, oral solution or syrup: 2.5 mg once daily; ≥12 years Same as adult dose. Treatment or dosage recommendations may vary among countries and individual products (refer to specific product guidelines).
Renal Impairment
Initially, 5 mg every other day. Dosage recommendations may vary among countries and individual products (refer to specific product guidelines).
Hepatic Impairment
Initially, 5 mg every other day. Dosage recommendations may vary among countries and individual products (refer to specific product guidelines).
Administration
May be taken with or without food.
Special Precautions
Patients with medical or familial history of seizure disorders. Patients who are slow or poor metabolisers of desloratadine may have an increased risk of adverse effects. Renal and hepatic impairment. Children. Pregnancy and lactation.
Adverse Reactions
Significant: Increased risk of seizures (particularly in children). Very rarely, hypersensitivity reactions (e.g. anaphylaxis). Gastrointestinal disorders: Dry mouth; diarrhoea (mainly in children <2 years). General disorders and administration site conditions: Fatigue; fever (mainly in children <2 years). Nervous system disorders: Headache. Psychiatric disorders: Insomnia (mainly in children <2 years). Respiratory, thoracic and mediastinal disorders: Pharyngitis; upper respiratory tract infection, cough (mainly in children <2 years).
Obtain renal function test and LFT at baseline. Monitor for signs and symptoms of hypersensitivity reactions.
Drug Interactions
May increase plasma concentrations with ketoconazole, erythromycin, azithromycin, fluoxetine, and cimetidine.
Lab Interference
May diminish the wheal and flare reactions to skin test antigens.
Action
Description: Mechanism of Action: Desloratadine, the major active metabolite of loratadine, is a non-sedating, long-acting antihistamine. It selectively blocks peripheral histamine H1-receptors. Onset: Within 1 hour. Duration: 24 hours. Pharmacokinetics: Absorption: Well absorbed. Time to peak plasma concentration: Approx 3 hours. Distribution: Enters breast milk. Volume of distribution: Approx 49 L/kg. Plasma protein binding: 82-87% (desloratadine); 85-89% (3-hydroxydesloratadine). Metabolism: Extensively metabolised in the liver into the active metabolite, 3-hydroxydesloratadine, which undergoes further glucuronidation; enzyme(s) responsible for desloratadine metabolism is not yet identified. Decreased metabolism in slow metabolisers of desloratadine. Excretion: Via urine (41%); faeces (47%). Elimination half-life: Approx 27 hours.
Chemical Structure
Desloratadine Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 124087, Desloratadine. https://pubchem.ncbi.nlm.nih.gov/compound/Desloratadine. Accessed May 26, 2022.
Storage
Store between 15-30°C. Storage recommendations may vary among countries or individual products. Refer to specific product guidelines.
Sign Out
